Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Relay Therapeutics (NASDAQ:RLAY) had its price target boosted by stock analysts at Wells Fargo & Company from $13.00 to $15.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 46.20% from the company’s current price.

Other research analysts have also recently issued reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Relay Therapeutics in a research report on Friday, January 9th. Oppenheimer raised shares of Relay Therapeutics from a “market perform” rating to an “outperform” rating and set a $14.00 price target for the company in a research note on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.40.

Relay Therapeutics Stock Performance

Relay Therapeutics stock opened at $10.26 on Friday. Relay Therapeutics has a fifty-two week low of $1.77 and a fifty-two week high of $11.43. The stock has a market cap of $1.78 billion, a P/E ratio of -6.33 and a beta of 1.59. The firm’s fifty day moving average price is $8.37 and its 200-day moving average price is $6.74.

Relay Therapeutics (NASDAQ:RLAY) last posted its earnings results on Thursday, February 26th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.06. The business had revenue of $7.00 million for the quarter, compared to analysts’ expectations of $4.34 million. Sell-side analysts predict that Relay Therapeutics will post -2.55 earnings per share for the current year.

Insider Transactions at Relay Therapeutics

In other Relay Therapeutics news, CEO Sanjiv Patel sold 43,168 shares of the stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $7.82, for a total transaction of $337,573.76. Following the transaction, the chief executive officer directly owned 661,041 shares in the company, valued at $5,169,340.62. This trade represents a 6.13% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Donald A. Bergstrom sold 18,895 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, January 27th. The stock was sold at an average price of $7.62, for a total transaction of $143,979.90. Following the transaction, the insider directly owned 422,733 shares in the company, valued at $3,221,225.46. This trade represents a 4.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 93,302 shares of company stock worth $724,355 in the last three months. Corporate insiders own 4.87% of the company’s stock.

Institutional Trading of Relay Therapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Franklin Resources Inc. lifted its stake in shares of Relay Therapeutics by 130.4% in the 2nd quarter. Franklin Resources Inc. now owns 394,122 shares of the company’s stock valued at $1,364,000 after acquiring an additional 223,042 shares during the last quarter. Congress Asset Management Co. grew its position in Relay Therapeutics by 160.9% during the 3rd quarter. Congress Asset Management Co. now owns 408,842 shares of the company’s stock worth $2,134,000 after acquiring an additional 252,142 shares during the last quarter. Geode Capital Management LLC lifted its position in Relay Therapeutics by 5.2% in the second quarter. Geode Capital Management LLC now owns 3,229,666 shares of the company’s stock valued at $11,176,000 after purchasing an additional 159,548 shares during the last quarter. Acadian Asset Management LLC lifted its position in Relay Therapeutics by 16.5% in the second quarter. Acadian Asset Management LLC now owns 794,619 shares of the company’s stock valued at $2,747,000 after purchasing an additional 112,591 shares during the last quarter. Finally, Bank of Montreal Can boosted its stake in shares of Relay Therapeutics by 73.6% during the second quarter. Bank of Montreal Can now owns 55,174 shares of the company’s stock valued at $191,000 after purchasing an additional 23,396 shares during the period. 96.98% of the stock is owned by institutional investors.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.